Objective To investigate in a cross-sectional study the effect of serum-derived exosomes on primary human blood monocyte-derived macrophages (MDMs) comparing exosomes from healthy donors vs patients with relapsing-remitting multiple sclerosis in remission and in relapse and to assess whether the response correlates with exosomal Epstein-Barr virus (EBV) protein expression. Methods A total of 45 serum-derived exosome preparations were isolated from patients and healthy controls and verified for the expression of exosomal and EBV markers. MDMs were differentiated from monocytes for 7 days and incubated for 24 hours with exosomes, and then, cell supernatants were collected for cytokine measurement by cytometric bead array. Cells were immunophenotyped before and after differentiation. Results Serum-derived exosomes of patients with multiple sclerosis (MS) expressed higher levels of EBV proteins than healthy controls. Of interest, expression of EBV nuclear antigen EBNA1 and latent membrane proteins LMP1 and 2A was higher on exosomes derived from patients with active RRMS compared with healthy controls and stable patients. After data normalization, we observed that incubation with EBV(+) exosomes induced CXCL10 and CCL2 secretion by MDMs. MDMs differentiated from patients with active disease were better secretors of CXCL10 and other interferon-γ–inducible chemokines, including CCL2 and CXCL9, than MDMs from healthy and stable MS groups. MDMs from active patients had a higher frequency of a CD14(++) subset that correlated with the secreted CXCL10. Conclusion Exosomes expressing EBV proteins correlate with disease activity and induce an inflammatory response in MDMs that is compounded by the origin of the responder cells.

Emerging evidence implicates the envelope protein of human endogenous retrovirus type W (pHERV-W ENV) in the pathogenesis of multiple sclerosis (MS); however, its clinical utility as a biomarker remains incompletely defined. In this study, we demonstrate that pHERV-W ENV is enriched on serum-derived exosomes in patients with relapsing-remitting MS (RRMS), where it reflects both current disease activity and future risk. Exosomal pHERV-W ENV levels were profiled across three cohorts: (1) a cross-sectional cohort including healthy controls, stable MS patients, and patients with active disease; (2) a longitudinal RRMS cohort with samples collected before, during, and after episodes of disease activity; and (3) a retrospective longitudinal cohort of newly diagnosed RRMS patients with three years of follow-up. We observed an increase in exosomal pHERV-W ENV expression during active disease, followed by a decline at follow-up. Levels of pHERV-W ENV expression during active disease positively correlated with Epstein-Barr virus (EBV)-derived latent membrane protein 2 A (LMP2A) expression, supporting an association between endogenous retroviral expression and EBV activity. Flow cytometric profiling of immune cell subsets identified monocytes and B cells as the predominant sources of circulating pHERV-W ENV. Longitudinal profiling further revealed coordinated immune and vascular activation during active disease, including a significant positive correlation between exosomal pHERV-W ENV and the costimulatory molecule CD40. Notably, high baseline levels of exosomal pHERV-W ENV were associated with greater total disease activity events, defined as the sum of clinical relapses and MRI activity (new/enlarging T2 or gadolinium-enhancing (Gd+) lesions) over three years, as well as with accelerated loss of “No Evidence of Disease Activity” (NEDA) status over time. These findings suggest that exosomal pHERV-W ENV expression may serve as a dynamic, non-invasive biomarker of disease activity with prognostic value in MS.

Background: Thromboxane A₂ is derived from arachidonic acid through the action of cyclooxygenases and thromboxane synthase. It is mainly formed in blood platelets upon activation and plays an important role in aggregation. Aspirin is effective in reducing the incidence of complications following acute coronary syndrome and stroke. The anti-thrombotic effect of aspirin is obtained through the irreversible inhibition of cyclooxygenases. Analogues of 12-hydroxyeicosatetraenoic acid and 13-hydroxyocatdecadienoic acid were shown previously to modulate platelet activation and to block thromboxane receptors. Results and discussion: We synthesized 10 compounds based on the structures of analogues of 12-hydroxyeicosatetraenoic acid and 13-hydroxyocatdecadienoic acid and evaluated their effect on platelet aggregation triggered by arachidonic acid. The structure activity relationship was evaluated. Five compounds showed a significant inhibition of platelet aggregation and highlighted the importance of the lipidic hydrophobic hydrocarbon chain and the phenol group. Their IC₅₀ ranged from 7.5 ± 0.8 to 14.2 ± 5.7 μM (Mean ± S.E.M.). All five compounds decreased platelet aggregation and thromboxane synthesis in response to collagen whereas no modification of platelet aggregation in response to thromboxane receptor agonist, U46619, was observed. Using COS-7 cells overexpressing human cyclooxygenase-1, we showed that these compounds are specific inhibitors of cyclooxygenase-1 with IC₅₀ ranging from 1.3 to 12 μM. Docking observation of human recombinant cyclooxygenase-1 supported a role of the phenol group in the fitting of cyclooxygenase-1, most likely related to hydrogen bonding with the Tyr 355 of cyclooxygenase-1. Conclusions: In conclusion, the compounds we synthesized at first based on the structures of analogues of 12 lipoxygenase metabolites showed a role of the phenol group in the anti-platelet and anti-cyclooxygenase-1 activities. These compounds mediate their effects via blockade of cyclooxygenase-1.

Multidrug-resistant Acinetobacter baumannii is a major nosocomial pathogen for which bacteriophages are being explored as alternative antibacterial agents. In this study, we isolated and characterized AUBFM01, a lytic phage active against MDR A. baumannii, and performed an initial assessment of its interaction with PMA-differentiated THP-1 macrophages. AUBFM01 was evaluated by host range testing, adsorption and one-step growth assays, lytic activity, stability testing, biofilm disruption, whole-genome sequencing, and flow cytometry-based macrophage profiling. The phage showed rapid adsorption, a short latent period of approximately 30 min, and a burst size of about 165 phage particles per infected cell. It remained stable under moderate temperature and near-neutral pH conditions and significantly reduced preformed A. baumannii biofilm biomass in vitro. Genomic analysis identified a 41,354-bp double-stranded DNA genome lacking detectable lysogeny-associated genes, antibiotic resistance determinants, and known bacterial virulence factors. In THP-1 macrophages, AUBFM01 exposure was associated with reduced cell viability and with enrichment of a resting/intermediate-like CD86-defined phenotype among the remaining cells, including after endotoxin reduction. These findings identify AUBFM01 as a lytic anti-Acinetobacter phage with antibiofilm activity and notable macrophage-associated effects that warrant further mechanistic and safety investigation.

Les statines sont des molécules hypocholestérolémiantes, inhibiteurs compétitifs de l'hydroxyméthylglutaryl-CoA réductase, possédant des propriétés anti-inflammatoires et anti-oxydantes dépendantes et indépendantes de leur capacité à réduire le cholestérol. L'hème-oxygénase-1, une enzyme responsable du catabolisme de l'hème participe à la résolution de l'inflammation, notamment via ses propriétés anti-oxydantes. Le système enzymatique cyclooxygénase-2/prostaglandine synthase-1 microsomale catalyse la transformation de l'acide arachidonique en prostaglandine E2, médiateur biologique important dans la régulation de l'hémostase des vaisseaux, la croissance cellulaire, l'inflammation et la douleur. La cyclooxygenase-2 et l'heme-oxygenase-1 étant des cibles des statines, et jouant un rôle majeur dans l'inflammation et la fibrose, le but de ce travail a été d'élucider les mécanismes moléculaires impliqués dans la régulation de l'expression de ces enzymes par les statines dans les macrophages et les fibroblastes. Dans les fibroblastes, nous avons démontré que l'induction de l'hème-oxygénase-1 par deux statines différentes, la simvastatine et la fluvastatine, est dépendante de la voie du mévalonate et de la géranygéranylation des protéines. Nous avons pu également démontrer le rôle des facteurs de transcription CCAAT/enhancer-binding protein beta et gamma et upstream stimulatory factor 1 ou 2 dans cette induction, en utilisant des ARN interférants. Dans les macrophages, nous avons mis en évidence que les statines induisent l'hème-oxygénase-1 par un mécanisme dépendant du monoxyde d'azote. La petite protéine G Rho A/C semble être impliquée dans cette régulation ainsi que le facteur de transcription CCAAT/enhancer-binding protein beta. Finalement, nous avons analysé le rôle des statines dans la régulation des cyclooxygénase-2 et la prostaglandine synthase-1 microsomale dans des myofibroblastes hépatiques humains. Nous avons mis en évidence que les statines induisent l'expression de ces deux enzymes, par un mécanisme impliquant la voie de la Rho A/C. La conséquence de cette activation est une libération de la prostaglandine E2 qui inhibe la prolifération des myofibroblastes hépatiques. Au niveau transcriptionnel, l'élément de réponse nuclear factor-kappa B et cAMP response element/E box régions ainsi que GATA les régions riches en GC participent à la régulation des promoteurs de la cyclooxygénase-2 et de la prostaglandine synthase-1 microsomale, respectivement. En resumé, nos travaux confirment que les statines jouent un rôle protecteur dans les macrophages et les fibroblastes en induisant hème-oxygénase-1, la cyclooxygénase-2 et la prostaglandine synthase-1 microsomale, des enzymes qui jouent un rôle majeur dans le contrôle de l'inflammation et la fibrose.